
|Articles|February 1, 2005
Studies confirm utility of fixed-combination glaucoma drug
New Orleans—Twice-daily administration of a fixed-combination product containing brimonidine 0.2% plus timolol 0.5% (Combigan, Allergan Inc.) safely and effectively lowers IOP, according to the pooled results of two 12-month, randomized, double-masked, phase III studies.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Rayner announces Sophi Phaco System in the US
2
Ophthalmology pipeline watch: Key trial results and PDUFA dates for Q1 2026
3
Ocugen releases positive preliminary 12-month data from phase 2 ArMaDa trial
4
STAAR, Broadwood reach cooperation agreement, restructure board after terminated Alcon deal
5














































